Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Uridine‑5′‑diphosphate‑2‑deoxy‑2‑fluoro‑alpha‑D‑galactose is a synthetic nucleotide sugar analog in which the galactose moiety is modified by fluorination at the 2-position and removal of the corresponding hydroxyl group. It belongs to the class of pyrimidine nucleotide sugars and serves as an experimental substrate for glycosyltransferases in biochemical research. The compound is not approved for therapeutic use but is used primarily as a tool molecule to study glycosylation processes and enzyme specificity. Its mechanism involves acting as a donor substrate in enzymatic glycosylation reactions[1][3][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-galactose.